
    
      The relapsed/refractory ALL patients will receive FC (F,Fludarabine，C，Cyclophosphamide)
      chemotherapy followed by infusion of allogenic or autologous CD19-Targeted CAR-T cells.No
      graft-versus-host disease (GVHD) prevention will be conducted before or after infusion.
      Dose-limiting toxicity,incidence of adverse events and disease response will be detected
      post-infusion.
    
  